Unexplained fever in children – benefits and challenges of FDG‐PET / CT

Feasibility of ultra-low-activity 18F-FDG PET/CT imaging in children

OBJECTIVES

To investigate the feasibility of paediatric 18F-FDG total-body PET/CT imaging with an ultra-low activity and explore an optimized acquisition time range.

METHODS

A total of 38 paediatric patients were prospectively enrolled and underwent dynamic total-body PET/CT imaging using ultra-low 18F-FDG activity (0.37 MBq/kg). The 60-minute list-mode raw data were acquired and then reconstructed as static PET images by using 50-51, 50-52, 50-53, 50-54, 50-55, 50-58, 50-60, and 45-60 minutes data, which were noted as G1, G2, G3, G4, G5, G8, G10, and G15, respectively. Image qualities were subjectively evaluated using the Likert scale and were objectively evaluated by the quantitative metrics including standard uptake value (SUV), signal-to-noise ratio (SNR), target-to-background ratio (TBR), and contrast-to-noise ratio (CNR).

RESULTS

The injected activity of FDG was 13.38 ± 5.68 MBq (4.40-28.16 MBq) and produced 0.58 ± 0.19 mSv (0.29-1.04 mSv) of effective dose. The inter-reader agreement of subjective image quality was excellent (kappa = 0.878; 95% CI, 0.845-0.910). The average scores of image quality for G1-G15 were 1.10 ± 0.20, 2.03 ± 0.26, 2.66 ± 0.35, 3.00 ± 0.27, 3.32 ± 0.34, 4.25 ± 0.30, 4.49 ± 0.36, and 4.70 ± 0.37, respectively. All image scores are above 3, and all lesions are detectable starting from G8. SNRs of backgrounds, TBRs, and CNRs were significant differences from the control group before G8 (all P < 0.05).

CONCLUSION

The image quality of the 8 min acquisition for paediatric 18F-FDG total-body PET/CT with an ultra-low activity could meet the diagnostic requirements.

ADVANCES IN KNOWLEDGE

This study confirms the feasibility of ultra-low dose PET imaging in children, and its methods and findings may guide clinical practice. Paediatric patients will benefit from reduced radiation doses.

Long Axial Field-of-View PET/CT: New Opportunities for Pediatric Imaging

The combined use of Positron Emission Tomography (PET) and Computed Tomography (CT) has become increasingly vital for diagnosing and managing oncological and infectious diseases in pediatric patients. The introduction of long axial field-of-view (LAFOV) PET/CT scanners, also known as "Total Body PET/CT," marks a significant advancement in nuclear medicine. This new technology enables faster pediatric imaging with substantially reduced radiation exposure and essentially eliminates the need for sedation, addressing previous critical concerns in pediatric imaging. This review will explore the applications and challenges of LAFOV PET/CT in pediatric imaging, highlight the benefits observed at two Danish hospitals, and evaluate its potential to transform the management of pediatric patients.

Sedation-free pediatric [18F]FDG imaging on totalbody PET/CT with the assistance of artificial intelligence

PURPOSE

While sedation is routinely used in pediatric PET examinations to preserve diagnostic quality, it may result in side effects and may affect the radiotracer's biodistribution. This study aims to investigate the feasibility of sedation-free pediatric PET imaging using ultra-fast total-body (TB) PET scanners and deep learning (DL)-based attenuation and scatter correction (ASC).

METHODS

This retrospective study included TB PET (uExplorer) imaging of 35 sedated pediatric patients under four years old to determine the minimum effective scanning time. A DL-based ASC method was applied to enhance PET quantification. Both quantitative and qualitative assessments were conducted to evaluate the image quality of ultra-fast DL-ASC PET. Five non-sedated pediatric patients were subsequently used to validate the proposed approach.

RESULTS

Comparisons between standard 300-second and ultra-fast 15-second imaging, CT-ASC and DL-ASC ultra-fast 15-second images, as well as DL-ASC ultra-fast 15-second images in non-sedated and sedated patients, showed no significant differences in qualitative scoring, lesion detectability, and quantitative Standard Uptake Value (SUV) (P = ns).

CONCLUSIONS

This study demonstrates that pediatric PET imaging can be effectively performed without sedation by combining ultra-fast imaging techniques with a DL-based ASC. This advancement in sedation-free ultra-fast PET imaging holds potential for broader clinical adoption.

Intelligent ultrafast total-body PET for sedation-free pediatric [18F]FDG imaging

PURPOSE

This study aims to develop deep learning techniques on total-body PET to bolster the feasibility of sedation-free pediatric PET imaging.

METHODS

A deformable 3D U-Net was developed based on 245 adult subjects with standard total-body PET imaging for the quality enhancement of simulated rapid imaging. The developed method was first tested on 16 children receiving total-body [18F]FDG PET scans with standard 300-s acquisition time with sedation. Sixteen rapid scans (acquisition time about 3 s, 6 s, 15 s, 30 s, and 75 s) were retrospectively simulated by selecting the reconstruction time window. In the end, the developed methodology was prospectively tested on five children without sedation to prove the routine feasibility.

RESULTS

The approach significantly improved the subjective image quality and lesion conspicuity in abdominal and pelvic regions of the generated 6-s data. In the first test set, the proposed method enhanced the objective image quality metrics of 6-s data, such as PSNR (from 29.13 to 37.09, p < 0.01) and SSIM (from 0.906 to 0.921, p < 0.01). Furthermore, the errors of mean standardized uptake values (SUVmean) for lesions between 300-s data and 6-s data were reduced from 12.9 to 4.1% (p < 0.01), and the errors of max SUV (SUVmax) were reduced from 17.4 to 6.2% (p < 0.01). In the prospective test, radiologists reached a high degree of consistency on the clinical feasibility of the enhanced PET images.

CONCLUSION

The proposed method can effectively enhance the image quality of total-body PET scanning with ultrafast acquisition time, leading to meeting clinical diagnostic requirements of lesion detectability and quantification in abdominal and pelvic regions. It has much potential to solve the dilemma of the use of sedation and long acquisition time that influence the health of pediatric patients.

EANM consensus document on the use of [18F]FDG PET/CT in fever and inflammation of unknown origin

PURPOSE

Patients with fever and inflammation of unknown origin (FUO/IUO) are clinically challenging due to variable clinical presentations with nonspecific symptoms and many differential diagnoses. Positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is increasingly used in FUO and IUO, but the optimal diagnostic strategy remains controversial. This consensus document aims to assist clinicians and nuclear medicine specialists in the appropriate use of [18F]FDG-PET/CT in FUO and IUO based on current evidence.

METHODS

A working group created by the EANM infection and inflammation committee performed a systematic literature search based on PICOs with "patients with FUO/IUO" as population, "[18F]FDG-PET/CT" as intervention, and several outcomes including pre-scan characteristics, scan protocol, diagnostic yield, impact on management, prognosis, and cost-effectiveness.

RESULTS

We included 68 articles published from 2001 to 2023: 9 systematic reviews, 49 original papers on general adult populations, and 10 original papers on specific populations. All papers were analysed and included in the evidence-based recommendations.

CONCLUSION

FUO and IUO remains a clinical challenge and [18F]FDG PET/CT has a definite role in the diagnostic pathway with an overall diagnostic yield or helpfulness in 50-60% of patients. A positive scan is often contributory by directly guiding treatment or subsequent diagnostic procedure. However, a negative scan may be equally important by excluding focal disease and predicting a favorable prognosis. Similar results are obtained in specific populations such as ICU-patients, children and HIV-patients.

Fever of unknown origin in pediatrics: role of nuclear medicine

Fever of unknown origin (FUO) is a debated issue in numerous scientific studies in adult patients with a not jet-defined workflow in a clinical and diagnostic setting. Few works are published about pediatric patients even if FUO represents a challenging, not infrequent scenario in hospital and outpatient recovery. The fever might be the onset symptom of a transient mild infection or the beginning of a more difficult-to-diagnose and serious pathological condition. In the adult workflow 18FDG PET-CT is nowadays playing a relevant role, considering the limited spread of conventional 99mTc-HMPAO-White Blood Cells scintigraphy. It represents a robust tool for diagnosing the eventual site of infection, but it is limited by procedural complexity and long duration, up to 24 hours. The WBC-scintigraphy is also not suitable for children, only for young adults or adolescents, considering the relevant blood sample entity and the procedural risk for sensitive subjects. The most assessed clinical and diagnostic know-how on Pediatric FUO are summarized and a synthetic flow-chard is presented to support the clinical management and to choose the best diagnostic pathway.

Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis

Sarcoidosis-associated uveitis, is the predominant ocular sarcoidosis presentation, which affects both adults and children. For adults, international ocular sarcoidosis criteria (IWOS) and sarcoidosis-associated uveitis criteria (SUN) are defined. However, for children they are not yet established internationally. Due to the specificity of pediatric manifestations of sarcoidosis, this task is even more challenging. In children, sarcoidosis is subdivided into Blau syndrome and early-onset sarcoidosis (BS/EOS) affecting younger children (< 5 years) and the one affecting older children with clinical presentation resembling adults. Differential diagnosis, clinical work-up as well as diagnostic criteria should be adapted to each age group. In this article, we review the clinical manifestation of sarcoidosis-associated uveitis in adults and children and the sensitivity and specificity of various ocular sarcoidosis diagnostic modalities, including chest X-ray and CT, FDG PET-CT, gallium-67 scintigraphy, bronchoalveolar lavage fluid, genetic testing for NOD2 mutations and serum biomarkers, such as ACE, lysozyme and IL2R.

Aetiology of Acute Undifferentiated Fever Among Children Under the Age of Five in Vietnam: A Prospective Study

BACKGROUND

To investigate the aetiology of acute undifferentiated fever (AUF) among children under the age of five in Vietnam.

METHODS

This prospective study was conducted in the Thai Binh paediatric hospital, between July 2020 and July 2021 among children with AUF at admission. Real-time PCR testing 18 microbial pathogens were done on blood samples.

RESULTS

286 children were included, with median age of 16 months. 64.7% were male. 53.9% were positive for at least one pathogen by PCR. Enterovirus, human herpesvirus 6, adenovirus, and varicella zoster virus PCR were positive for 31.1, 12.6, 1.4, and 1.0% patients, respectively. Other pathogens tested negative by PCR. During the hospital stay, based on clinical criteria 47.2% children secondarily presented with signs of respiratory tract infections, 18.9% had hand, foot and mouth disease, 4.6% had chickenpox. 4.2% presented signs of central nervous system infections, 1.0% had dengue (antigenic test) and 1.0% had signs of gastrointestinal infection. Finally, 23.1% patients presented a fever with or without a rash and no other symptoms and ultimately received a diagnosis of AUF.

CONCLUSION

Real-time PCR of blood is useful for detecting pathogens and diagnosing infectious causes of AUF. Further prospective studies with blood and urine culture testing and PCR investigation of not only blood but also cerebrospinal fluid, throat, and skin samples according to symptoms would be of interest to confirm the predominance of viral infections in children with AUF and to guide therapeutic options.